



Supplementary Figure 1. Clinical and pathological outcomes of patients treated with neoadjuvant systemic therapy stratified according to MKS and ERS status A, B) PathR rates (A) and 4-year distant event-free survival rates (B) in patients receiving taxane-anthracycline-based neoadjuvant chemotherapy at MD Anderson Cancer Center. C, D) 4-year distant event-free survival rates in patients with MKS^{hi}/ERS^{hi} (C) and MKS^{hi}/ERS^{lo} (D) tumors according to pathological response. E, F) Ki67 levels (E) and MKS expression (F) at surgery in patients receiving neaodjuvant AI in the POETIC study.









MKS^{hi}/ERS^{lo}

F


MKS^{lo}/ERS^{hi} N

MKS^{lo}/ERS^{lo}


MKS^{hi}/ERS^{hi} Mł

MKS^{hi}/ERS^{lo}


Supplementary Figure 2. Clinical outcomes and genomic alterations of ER+/HER2- tumors stratified according to MKS and ERS status in TCGA A) 5-year Overall Survival. B) Most frequently mutated genes




0




Supplementary Figure 3. Expression of potential predictive biomarkers for CDK4/6 inhibitors in ER+/HER2- tumors stratified according to MKS and ERS status in the TCGA dataset. A) RB signature expression levels. B) Interferon-Related Palbociclib-Resistance Signature expression levels. **C**) Cyclin E expression levels




Supplementary Figure 4. Tumor mutational burden (TMB) in breast cancer subgroups in TCGA. A) TMB in ER+/HER2- tumors stratified according to MKS and ERS status. B) TMB in the whole breast cancer cohort stratified according to ER and HER2 status. C) TMB in ER+/HER2- tumors stratified according to ERS quartiles. D) TMB in MKS^{hi} tumors stratified according to ERS quartiles. E, F) TMB in ER+/HER2- tumors (whole cohort and molecular subgroups) stratified according to PIK3CA (E) and TP53 (F) mutation status



Supplementary Figure 5. Expression of potential predictive biomarkers for immune checkpoint inhibitors in ER+/HER2- tumors in TCGA dataset. TILs metagene (A, B, C) and T cell-inflamed GEP (D, E, F) expression levels in ER+/HER2- tumors stratified according to MKS and ERS status (A and C), in ER+/HER2- tumors stratified according to ERS quartiles (B and D), in MKS^{hi} tumors stratified according to ERS quartiles (C and F)





Supplementary Figure 6. Distribution of ER (A) and PgR (B) expression levels by IHC within MKS^{hi}/ERS^{hi} (red bars) and MKS^{hi}/ERS^{lo} (orange bars) tumors in TCGA

